Aprepitant injectable emulsion
HTX-019-202
Phase 2 small_molecule terminated
Quick answer
Aprepitant injectable emulsion for COVID-19 is a Phase 2 program (small_molecule) at Heron Therapeutics with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Heron Therapeutics
- Indication
- COVID-19
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- terminated